Placulumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | TNF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C3404H5262N902O1036S22 |
| Molar mass | 76104.14 g·mol−1 |
Placulumab is a human monoclonal antibody designed for the treatment of inflammatory diseases.[1]
This drug was developed by Teva Pharmaceutical Industries, Inc. As of 2012, development of placulumab has been discontinued.
References
[edit]
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |